A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Ipatasertib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms IPATunity130
- Sponsors Chugai Pharmaceutical; Roche; Roche Farma
- 13 Nov 2019 Last checked against Clinical Trials Registry - India
- 05 Nov 2018 Planned End Date changed from 31 Mar 2021 to 24 Dec 2021.
- 05 Nov 2018 Planned primary completion date changed from 31 Mar 2021 to 24 Dec 2021.